Special Issue

Gene and Cell Therapies for Lung Cancer Treatment

Message from the Guest Editor

This Special Issue is dedicated to the exciting topics of translational medicine, gene and cell therapy for the treatment of lung cancer. Lung cancer is the leading cause of cancer death. Carcinogenesis is associated with smoking and air pollution. Seventy percent of patients are inoperable at the time of diagnosis, and therefore prevention, early detection and fruitful translational research are of equal importance. Treatment depends on the stage and usually consists of surgery (if possible), chemotherapy and radiotherapy. Gene and cell therapy are promising new approaches. Gene therapy involves genome editing of tumor /immune cells using the CRISPR/Cas9 method. Cellular therapy of CAT-T lymphocytes has been previously implemented on hemoblastosis and is now investigated in lung cancer as a solid tumor. CAR-T lymphocytes are technologically armed for the effective destruction of tumor cells in vivo, recognizing specific tumor antigens in a MHC-independent manner. Mature bone-marrow mesenchymal stem cells could successfully serve as carriers of TRAIL protein, a ligand for cell-death receptor on tumor cells, causing their apoptosis.

Guest Editor

Prof. Dr. Merica Glavina-Durdov
Kliničći Bolnički Centar Split, Split, Croatia

Deadline for manuscript submissions

closed (30 September 2022)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/119638

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).